Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38.3M
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
26M
-
Shares change
-
+284K
-
Total reported value, excl. options
-
$411M
-
Value change
-
+$4.52M
-
Number of buys
-
23
-
Number of sells
-
-19
-
Price
-
$15.80
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q3 2023
60 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26M shares
of 38.3M outstanding shares and own 67.89% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), MPM ASSET MANAGEMENT LLC (4.43M shares), 5AM Venture Management, LLC (4.41M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3M shares), BlackRock Inc. (1.4M shares), Redmile Group, LLC (1.28M shares), WELLINGTON MANAGEMENT GROUP LLP (1.05M shares), VANGUARD GROUP INC (1.02M shares), StepStone Group LP (761K shares), and TCG Crossover Management, LLC (585K shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.